15 results on '"Sekine, Masaaki"'
Search Results
2. CARD11 mutation and HBZ expression induce lymphoproliferative disease and adult T-cell leukemia/lymphoma.
- Author
-
Kameda, Takuro, Shide, Kotaro, Kamiunten, Ayako, Kogure, Yasunori, Morishita, Daisuke, Koya, Junji, Tahira, Yuki, Akizuki, Keiichi, Yokomizo-Nakano, Takako, Kubota, Sho, Marutsuka, Kosuke, Sekine, Masaaki, Hidaka, Tomonori, Kubuki, Yoko, Kitai, Yuichi, Matsuda, Tadashi, Yoda, Akinori, Ohshima, Takayuki, Sugiyama, Midori, and Sashida, Goro
- Abstract
Adult T-cell leukemia/lymphoma (ATL) is caused by human T-cell leukemia virus type 1 (HTLV-1). In addition to HTLV-1 bZIP factor (HBZ), a leukemogenic antisense transcript of HTLV-1, abnormalities of genes involved in TCR-NF-κB signaling, such as CARD11, are detected in about 90% of patients. Utilizing mice expressing CD4
+ T cell-specific CARD11(E626K) and/or CD4+ T cell-specific HBZ, namely CARD11(E626K)CD4-Cre mice, HBZ transgenic (Tg) mice, and CARD11(E626K)CD4-Cre ;HBZ Tg double transgenic mice, we clarify these genes’ pathogenetic effects. CARD11(E626K)CD4-Cre and HBZ Tg mice exhibit lymphocytic invasion to many organs, including the lungs, and double transgenic mice develop lymphoproliferative disease and increase CD4+ T cells in vivo. CARD11(E626K) and HBZ cooperatively activate the non-canonical NF-κB pathway, IRF4 targets, BATF3/IRF4/HBZ transcriptional network, MYC targets, and E2F targets. Most KEGG and HALLMARK gene sets enriched in acute-type ATL are also enriched in double transgenic mice, indicating that these genes cooperatively contribute to ATL development.The oncogenic ability of mutant CARD11 (E626K), one of most frequently mutated genes in adult T-cell leukemia and its cooperative effect with HBZ expression, using the CD4 promoter-driven HBZ transgenic mouse model, is investigated. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
3. Prognosis of Indolent Adult T-Cell Leukemia/Lymphoma.
- Author
-
Kameda, Takuro, Shide, Kotaro, Tahira, Yuki, Sekine, Masaaki, Sato, Seiichi, Ishizaki, Junzo, Takeuchi, Masanori, Akizuki, Keiichi, Kamiunten, Ayako, Shimoda, Haruko, Toyama, Takanori, Maeda, Kouichi, Yamashita, Kiyoshi, Kawano, Noriaki, Kawano, Hiroshi, Hidaka, Tomonori, Yamaguchi, Hideki, Kubuki, Yoko, Kitanaka, Akira, and Matsuoka, Hitoshi
- Subjects
ADULT T-cell leukemia ,LYMPHOMAS ,BLOOD urea nitrogen ,SURVIVAL rate ,PROGNOSIS - Abstract
A retrospective chart survey of the clinical features of indolent adult T-cell leukemia/lymphoma (ATL) was conducted in the Miyazaki Prefecture, Japan. This study enrolled 24 smoldering-type ATLs, 10 favorable chronic-type ATLs, and 20 unfavorable chronic-type ATLs diagnosed between 2010 and 2018. Among them, 4, 3, and 10 progressed to acute-type ATLs during their clinical course. The median survival time (MST) in smoldering-type ATL and favorable chronic-type ATL was not reached, and their 4-year overall survival (OS) was 73% and 79%, respectively. Compared with this, the prognosis of unfavorable chronic-type ATL was poor. Its MST was 3.32 years, and the 4-year OS was 46% (p = 0.0095). In addition to the three features that determine the unfavorable characteristics of chronic-type ATL, namely, increased lactate dehydrogenase, increased blood urea nitrogen, and decreased albumin, the high-risk category by the indolent ATL-Prognostic Index, which was defined by an increment of soluble interleukin-2 receptor (sIL2-R) of >6000 U/mL, could explain the poor prognosis in indolent ATL patients. The level of sIL-2R might be an indicator of the initiation of therapy for indolent ATL. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Higher average chemotherapy dose intensity improves prognosis in patients with aggressive adult T‐cell leukemia/lymphoma.
- Author
-
Sekine, Masaaki, Kameda, Takuro, Shide, Kotaro, Maeda, Kouichi, Toyama, Takanori, Kawano, Noriaki, Takeuchi, Masanori, Kawano, Hiroshi, Sato, Seiichi, Ishizaki, Junzo, Kukita, Toshimasa, Kamiunten, Ayako, Akizuki, Keiichi, Tahira, Yuki, Shimoda, Haruko, Hidaka, Tomonori, Yamashita, Kiyoshi, Matsuoka, Hitoshi, Kitanaka, Akira, and Kubuki, Yoko
- Subjects
ADULT T-cell leukemia ,CANCER chemotherapy ,T-cell lymphoma ,LYMPHOMAS ,PROGNOSIS - Abstract
Objective and Method: Adult T‐cell leukemia/lymphoma (ATL) is an aggressive peripheral T‐cell lymphoma with poor prognosis. We retrospectively reviewed the medical records of 312 patients with aggressive ATL and analyzed the effect of chemotherapy dose intensity on prognosis in clinical practice. Result: As first‐line therapy, 62 patients underwent best supportive care (BSC) or single‐agent chemotherapy, and 235 underwent intensive chemotherapy. The median survival time (MST) was 0.58 years in the 312 total patients, and 0.13 years and 0.75 years in the BSC/single‐agent chemotherapy group and intensive chemotherapy group, respectively. The median average relative dose intensity (ARDI) of patients who received intensive chemotherapy was 60%. We divided patients into 3 groups according to ARDI. Those in the top tertile of ARDI (ARDI ≥ 75%, n = 82) had better overall survival compared with those in the intermediate tertile (45% ≤ ARDI < 75%, n = 79) (P <.0001), with MSTs of 4.69 and 0.75 years, respectively. The occurrence of organ dysfunction and infectious complications was comparable between the two ARDI groups. Conclusion: Higher ARDI improves prognosis in patients with aggressive ATL in clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. TP53 and PTEN mutations were shared in concurrent germ cell tumor and acute megakaryoblastic leukemia.
- Author
-
Akizuki, Keiichi, Sekine, Masaaki, Kogure, Yasunori, Kameda, Takuro, Shide, Kotaro, Koya, Junji, Kamiunten, Ayako, Kubuki, Yoko, Tahira, Yuki, Hidaka, Tomonori, Kiwaki, Takumi, Tanaka, Hiroyuki, Sato, Yuichiro, Kataoka, Hiroaki, Kataoka, Keisuke, and Shimoda, Kazuya
- Subjects
TERATOCARCINOMA ,ACUTE leukemia ,TUMOR suppressor genes ,ACUTE myeloid leukemia ,HEMATOLOGIC malignancies ,PRELEUKEMIA - Abstract
Background: The occurrence of a mediastinal germ cell tumor (GCT) and hematological malignancy in the same patient is very rare. Due to its rarity, there have been only two reports of the concurrent cases undergoing detailed genetic analysis with whole-exome sequencing (WES), and the possible clonal relationship between the both tumors remained not fully elucidated.Methods: We performed whole-exome sequencing analysis of mediastinal GCT and acute myeloid leukemia (AML) samples obtained from one young Japanese male adult patient with concurrent both tumors, and investigated the possible clonal relationship between them.Results: Sixteen somatic mutations were detected in the mediastinal GCT sample and 18 somatic mutations in the AML sample. Mutations in nine genes, including TP53 and PTEN both known as tumor suppressor genes, were shared in both tumors.Conclusions: All in our case and in the previous two cases with concurrent mediastinal GCT and AML undergoing with whole-exome sequencing analysis, TP53 and PTEN mutations were commonly shared in both tumors. These data not only suggest that these tumors share a common founding clone, but also indicate that associated mediastinal GCT and AML harboring TP53 and PTEN mutations represent a unique biological entity. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
6. Outcome of allogeneic hematopoietic cell transplantation in patients with adult T-cell leukemia.
- Author
-
Kamiunten, Ayako, Sekine, Masaaki, Kameda, Takuro, Akizuki, Keiichi, Tahira, Yuki, Shide, Kotaro, Shimoda, Haruko, Kato, Koji, Hidaka, Tomonori, Kubuki, Yoko, and Shimoda, Kazuya
- Abstract
Adult T-cell leukemia/lymphoma (ATL) is an aggressive peripheral T-cell neoplasm, and the outcome of patients with ATL after chemotherapy is poor. Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) is a curative treatment modality for ATL, and four factors, namely, age > 50 years, male recipient, lack of complete remission at transplantation, and transplantation of cord blood, were previously shown to be associated with poor survival. We retrospectively analyzed the outcome of 21 patients with ATL who had undergone allo-HSCT at our hospital during a 3-year period. Of 21 patients, all had at least one of the above risk factors, and 18 had two or more. With a median follow-up of 19.7 months for living patients, the 1- and 2-year overall survival (OS) rates after transplantation were 34% and 27%, respectively. All relapse/progression events occurred within 1 year after allo-HSCT, and the cumulative incidence of relapse/progression at 1 year after allo-HSCT was 46.9%. The 100-day and 1-year nonrelapse mortality (NRM) rates were 19% and 42%, respectively. No significant difference in OS was observed between myeloablative and reduced-intensity conditioning regimens. The 3-year OS (27%) of ATL patients who received allo-HSCT and who had at least one adverse factor was somewhat poorer than the 3-year OS of 33% identified in a nationwide study of allo-HSCT in ATL patients in Japan. The high relapse/progression and NRM rates are major problems to be solved to achieve better outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
7. Early/prefibrotic primary myelofibrosis in patients who were initially diagnosed with essential thrombocythemia.
- Author
-
Kamiunten, Ayako, Shide, Kotaro, Kameda, Takuro, Ito, Masafumi, Sekine, Masaaki, Kubuki, Yoko, Hidaka, Tomonori, Akizuki, Keiichi, Tahira, Yuki, Toyama, Takanori, Kawano, Noriaki, Marutsuka, Kousuke, Maeda, Kouichi, Takeuchi, Masanori, Kawano, Hiroshi, Sato, Seiichi, Ishizaki, Junzo, Shimoda, Haruko, Yamashita, Kiyoshi, and Matsuoka, Hitoshi
- Abstract
A new entity, namely early/prefibrotic primary myelofibrosis (PMF), was introduced as a subtype of PMF in the 2016 revised World Health Organization (WHO) criteria for myeloproliferative neoplasms (MPN). It was diagnosed based on histopathological features of bone marrow (BM) biopsy specimens together with clinical parameters [leukocytosis, anemia, elevated lactate dehydrogenase (LDH) values, and splenomegaly]. The aim of this study was to evaluate the prevalence of early/prefibrotic PMF in patients who were previously diagnosed with ET, and to compare clinical features at diagnosis and outcomes between early/prefibrotic PMF and essential thrombocythemia (ET) patients. BM biopsy samples obtained at the time of ET diagnosis were available in 42 patients. Sample reevaluation according to the 2016 revised WHO criteria revealed that early/prefibrotic PMF accounted for 14% of patients who were previously diagnosed with ET, which was comparable to the rates in previous reports. Compared to patients with ET, patients with early/prefibrotic PMF had higher LDH values and higher frequencies of splenomegaly. Overall, myelofibrosis-free and acute myeloid leukemia-free survivals were comparable between the 2 groups. Accurate diagnosis is required to clarify the clinical features of Japanese ET patients. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
8. Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan.
- Author
-
Kamiunten, Ayako, Shide, Kotaro, Kameda, Takuro, Sekine, Masaaki, Kubuki, Yoko, Ito, Masafumi, Toyama, Takanori, Kawano, Noriaki, Marutsuka, Kousuke, Maeda, Kouichi, Takeuchi, Masanori, Kawano, Hiroshi, Sato, Seiichi, Ishizaki, Junzo, Akizuki, Keiichi, Tahira, Yuki, Shimoda, Haruko, Hidaka, Tomonori, Yamashita, Kiyoshi, and Matsuoka, Hitoshi
- Subjects
BONE marrow diseases ,HEMORRHAGE ,SURVIVAL ,THROMBOCYTOSIS ,THROMBOSIS ,PREDICTIVE tests ,DISEASE incidence ,RETROSPECTIVE studies ,DISEASE progression ,LEUKOCYTE count ,DISEASE complications - Abstract
Polycythemia vera (PV) and essential thrombocythemia (ET) are associated with life-threatening thrombohemorrhagic events, and disease progression and development of non-hematological malignancies also reduce long-term survival. We retrospectively surveyed thrombohemorrhagic events and overall survival (OS) in 62 PV and 117 ET patients. The cumulative incidences of thrombohemorrhagic events in PV and ET patients were 11.3 and 10.3%, and the incidence rates were 2.42 and 1.85 per 100 person-years. The combined incidence rates of disease progression and development of non-hematological malignancies in PV and ET patients were 1.73 and 1.69 per 100 person-years. The incidence rates of thrombohemorrhagic events in our Japanese PV/ET patients were lower than those reported by most Western studies, but were comparable to those in the largest prospective observational study in ET patients. The combined incidence rates of disease progression and development of non-hematological malignancies were similar between Japanese and Western PV/ET patients. In ET patients, the conventional risk stratification model based on the presence of advanced age or history of thrombosis was useful to predict thrombosis risk, and both the conventional model and the International Prognostic Score of thrombosis in ET based on the above 2 risk factors plus increased leukocyte count could predict poor survival. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
9. Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice.
- Author
-
Sekine, Masaaki, Kubuki, Yoko, Kameda, Takuro, Takeuchi, Masanori, Toyama, Takanori, Kawano, Noriaki, Maeda, Kouichi, Sato, Seiichi, Ishizaki, Junzo, Kawano, Hiroshi, Kamiunten, Ayako, Akizuki, Keiichi, Tahira, Yuki, Shimoda, Haruko, Shide, Kotaro, Hidaka, Tomonori, Kitanaka, Akira, Yamashita, Kiyoshi, Matsuoka, Hitoshi, and Shimoda, Kazuya
- Subjects
ADULT T-cell leukemia ,T-cell lymphoma ,THERAPEUTIC use of monoclonal antibodies ,PROGRESSION-free survival ,ANTINEOPLASTIC agents ,LEUKEMIA treatment ,THERAPEUTICS - Abstract
Objective The efficacy of mogamulizumab in adult T-cell leukemia/lymphoma ( ATLL) was reported in a previous phase 2 study. Compared with patients in clinical trials, however, most patients in real-life settings have demonstrated worse outcomes. Method We retrospectively analyzed 96 patients with relapsed/refractory ATLL who received mogamulizumab treatment. Results Relapsed/refractory ATLL patients with a median age of 70 years received a median of five courses of mogamulizumab. Hematologic toxicity and skin rash were the most common adverse events, and both were manageable. Of 96 patients, 87 were evaluable for efficacy. The overall response rate was 36%, and the median progression-free survival ( PFS) and overall survival ( OS) from the start of mogamulizumab therapy were 1.8 and 4.0 months, respectively. Of the original 96 patients, only 25 fulfilled the inclusion criteria of the phase 2 study. Those who met the criteria demonstrated longer median PFS and OS durations of 2.7 and 8.5 months, respectively. The median OS from diagnosis in relapsed/refractory ATLL patients receiving mogamulizumab was 12 months, longer than the 5.8 months in a historical cohort without mogamulizumab. Conclusion In clinical practice, mogamulizumab exhibited antitumor activity in patients with relapsed/refractory ATLL, with an acceptable toxicity profile. Mogamulizumab therapy improved the OS of ATLL patients. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
10. Potentiated activation of VLA-4 and VLA-5 accelerates proplatelet-like formation.
- Author
-
Matsunaga, Takuya, Fukai, Fumio, Kameda, Takuro, Shide, Kotaro, Shimoda, Haruko, Torii, Eri, Kamiunten, Ayako, Sekine, Masaaki, Yamamoto, Shojirou, Hidaka, Tomonori, Kubuki, Yoko, Yokokura, Shigeyuki, Uemura, Makiko, Matsuoka, Akihito, Waki, Fusako, Matsumoto, Kensuke, Kanaji, Nobuhiro, Ishii, Tomoya, Imataki, Osamu, and Dobashi, Hiroaki
- Subjects
BLOOD platelets ,FIBRONECTINS ,CELL proliferation ,INTEGRINS ,MONOCLONAL antibodies ,TENASCIN ,PHORBOLS - Abstract
Fibronectin (FN) plays important roles in the proliferation, differentiation, and maintenance of megakaryocytic-lineage cells through FN receptors. However, substantial role of FN receptors and their functional assignment in proplatelet-like formation (PPF) of megakaryocytes are not yet fully understood. Herein, we investigated the effects of FN receptors on PPF using the CHRF-288 human megakaryoblastic cell line, which expresses VLA-4 and VLA-5 as FN receptors. FN and phorbol 12-myristate 13-acetate (PMA) were essential for inducing PPF in CHRF-288 cells. Blocking experiments using anti-β1-integrin monoclonal antibodies indicated that the adhesive interaction with FN via VLA-4 and VLA-5 were required for PPF. PPF induced by FN plus PMA was accelerated when CHRF-288 cells were enforced adhering to FN by TNIIIA2, a peptide derived from tenascin-C, which we recently found to induce β1-integrin activation. Adhesion to FN enhanced PMA-stimulated activation of extracellular signal-regulated protein kinase 1 (ERK1)/2 and enforced adhesion to FN via VLA-4 and VLA-5 by TNIIIA2-accelerated activation of ERK1/2 with FN plus PMA. However, c-Jun amino-terminal kinase 1 (JNK1), p38, and phosphoinositide-3 kinase (PI3K)/Akt were not stimulated by FN plus PMA, even with TNIIIA2. Thus, the enhanced activation of ERK1/2 by FN, PMA plus TNIIIA2 was responsible for acceleration of PPF with FN plus PMA. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
11. Acute myeloid leukemia in clinical practice: a retrospective population-based cohort study in Miyazaki Prefecture, Japan.
- Author
-
Matsunaga, Takuya, Yamashita, Kiyoshi, Kubuki, Yoko, Toyama, Takanori, Imataki, Osamu, Maeda, Kouichi, Kawano, Noriaki, Satou, Seiichi, Kawano, Hiroshi, Ishizaki, Junzo, Yoshida, Shuro, Kameda, Takuro, Sasaki, Tadashi, Sekine, Masaaki, Kamiunten, Ayako, Taniguchi, Yasuhiro, Hidaka, Tomonori, Katayose, Keiko, K-Shimoda, Haruko, and Shide, Kotaro
- Abstract
We performed a retrospective population-based cohort study of acute myeloid leukemia (AML) in Miyazaki Prefecture, Japan. Over 6 years, we diagnosed 221 patients (211 adults and 10 children) with AML, indicating an incidence of AML in Miyazaki Prefecture of 3.2 per 100,000 per year. In 193 adult patients with non-acute promyelocytic leukemia (APL), the proportion of patients with myelodysplasia, unfavorable risk karyotypes, antecedent hematologic diseases, prior chemotherapy for other malignancies, and small proportion of blasts in the marrow was higher in patients ≥65 years, and patients with poor performance status (PS) and higher WBC counts at diagnosis were more prevalent among patients ≥75 years. One-third of the adult non-APL patients met the inclusion criteria usually applied in clinical trials: de novo AML, age ≤64 years with PS 0-2 and no key organ dysfunction. The 5-year overall survival (OS) rate of adult non-APL patients was 21.1 % (patients ≤64 years, 33.8 %; 65-74 years, 21.6 %; ≥75 years, 0 %). Multivariate analysis revealed that French-American-British subtypes M0, M6, and M7, poor PS (3, 4), unfavorable risk karyotypes, and higher WBC counts at diagnosis were independent adverse prognostic factors associated with OS. This analysis provides real world data. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
12. Relationship between CYP3A5 Polymorphism and Tacrolimus Blood Concentration Changes in Allogeneic Hematopoietic Stem Cell Transplant Recipients during Continuous Infusion.
- Author
-
Yoshikawa, Naoki, Takeshima, Hidemi, Sekine, Masaaki, Akizuki, Keiichi, Hidaka, Tomonori, Shimoda, Kazuya, and Ikeda, Ryuji
- Subjects
STEM cell transplantation ,HEMATOPOIETIC stem cell transplantation ,TACROLIMUS ,CYTOCHROME P-450 CYP3A - Abstract
A polymorphism in the gene encoding the metabolic enzyme cytochrome P450 family 3 subfamily A member 5 (CYP3A5) is a particularly influential factor in the use of tacrolimus in Japanese patients. Those who are homozygotic for the *3 mutation lack CYP3A5 activity, which results in substantial individual differences in tacrolimus metabolism. The aim of this study was to analyze the relationship between individual differences in tacrolimus blood concentration changes and CYP3A5 polymorphisms in allogeneic hematopoietic stem cell transplantation recipients during the period of increasing blood concentration of the drug following treatment onset. This was a prospective observational cohort study, involving 20 patients administered tacrolimus by continuous infusion. The subjects were divided into the *1/*3 and *3/*3 groups based on CYP3A5 polymorphism analysis. The tacrolimus blood concentration/dose (C/D) ratio increased from day 1 and was largely stable on day 5, and a significant difference was observed between the *1/*3 and *3/*3 groups in the time course of the C/D ratio during this period (p < 0.05). This study reveals the effects of CYP3A5 polymorphism on continuous changes in tacrolimus blood concentration. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
13. Real-World Data on Clinical Features, Outcomes, and Prognostic Factors in Multiple Myeloma from Miyazaki Prefecture, Japan.
- Author
-
Akizuki, Keiichi, Matsuoka, Hitoshi, Toyama, Takanori, Kamiunten, Ayako, Sekine, Masaaki, Shide, Kotaro, Kameda, Takuro, Kawano, Noriaki, Maeda, Kouichi, Takeuchi, Masanori, Kawano, Hiroshi, Sato, Seiichi, Ishizaki, Junzo, Tahira, Yuki, Shimoda, Haruko, Hidaka, Tomonori, Yamashita, Kiyoshi, Kubuki, Yoko, and Shimoda, Kazuya
- Subjects
MULTIPLE myeloma ,PROGNOSIS ,STEM cell transplantation ,DIAGNOSIS ,MULTIVARIATE analysis ,PLASMACYTOMA - Abstract
The prognosis of multiple myeloma (MM) has improved with the introduction of novel agents. These data are largely derived from clinical trials and might not reflect real-world patient outcomes accurately. We surveyed real-world data from 284 patients newly diagnosed with MM between 2010 and 2018 in Miyazaki Prefecture. The median follow-up period was 32.8 months. The median age at diagnosis was 71 years, with 68% of patients aged >65 years. The International Staging System (ISS) stage at diagnosis was I in 18.4% of patients, II in 34.1%, and III in 47.5%. Bortezomib-containing regimens were preferred as initial treatment; they were used in 147 patients (51.8%). In total, 80% of patients were treated with one or more novel agents (thalidomide, lenalidomide, or bortezomib). Among 228 patients who were treated with novel agents as an initial treatment, the overall response rate (partial response (PR) or better) to initial treatment was 78.4%, and the median time to next treatment (TTNT) was 11.6 months. In the multivariate analysis, PR or better responses to initial treatment were independently favorable prognostic factors for TTNT. The median survival time after initial therapy for patients with novel agents was 56.4 months and 3-year overall survival (OS) was 70.4%. In multivariate analysis, ISS stage I/II disease and PR or better response to initial treatment, and autologous stem cell transplantation (ASCT) were identified as independent prognostic factors for overall survival (OS). [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. Corrosion-Resistant GMR Head for Over 1-TB Tape System.
- Author
-
Sekine, Masaaki, Watanabe, Takashi, Tamakawa, Yusuke, Shibata, Takuji, and Soda, Yutaka
- Subjects
MAGNETORESISTANCE ,ELECTRIC resistance ,MAGNETIC fields ,MAGNETIC properties ,EARTH resistance (Geophysics) ,DENSITY - Abstract
We have developed a corrosion-resistant giant magnetoresistance (GMR) head using a spin-valve (Ta/NiFe/CoNiFe/CuAu/CoNiFe/PtMn/Ta) film for an over 1-TB helical tape system. The magnetic properties of the corrosion-resistant GMR head were preserved during a Battelle Class II test for 20 days. The sense current shunting in the spacer layer of the spin-valve film (SV) was less for CuAu than for Cu due to the higher resistivity of CuAu. The interlayer-coupling field in the corrosion-resistant SV film was about 25% that in conventional SV films. Therefore, each layer of the corrosion-resistant SV film was designed so as to optimize the bias point. For stripe-heights in the range from 0.7 to 0.4 μm, the asymmetry of the head output was maintained at ±20%. The recording characteristics had a signal-to-noise ratio (SNR) of 19.5 dB with a 0.7 μm track width at a 254 kFCI linear density. Using this head, a tape system of over 1 TB per cassette is possible. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
15. DISSIPATIVE GAP MATERIAL IN TAPE HEADS.
- Author
-
SODA, YUTAKA and SEKINE, MASAAKI
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.